NFKB1 and Parkinson disease: While the specific inflammatory mediator(s) targeted by of NF-κB inhibition within microglial cells remains to be determined, these data suggest that inhibition of ROS production using NF-κB inhibitors may be a key component of the neuroprotection seen in PD patients [27].